OTC Cough, Cold & Allergy Medicine Market: Analysis of Opportunities Offered by High Growth Economies, Review till 2022

FACT.MR has been actively involved in offering comprehensive research data concerning various topics which are associated to industrial reference and investor utility. This particular research report titled “OTC Cough, Cold & Allergy Medicine Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022” has been added to the wide online database of FACT.MR which discusses the present as well as future market scenario. Readers can access knowledge related to market volume, regional expanse as well as competitive landscape prevailing in the global OTC Cough, Cold & Allergy Medicine market. In order to study development patterns, this smart assessment also focuses on market dynamics, which talks about drivers, restraints and opportunities estimated to influence the concerned market during the period until 2017 to 2022.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=71

Following insights from Fact.MR’s global OTC cough, cold and allergy market will be important for market’s future growth

1- The OTC cough, cold and allergy medicines market in Asia Pacific excluding Japan (APEJ) is anticipated to remain highly attractive throughout the assessment period. In 2017 and beyond, the region is projected to command for a noteworthy revenue share of the global market. This is primarily owing to dropping air quality and increase pollution that is resulting in higher occurrence of respiratory ailments. In addition, rapid adoption of OTC medicines owing to their convenience of purchase and cost-efficiency is facilitating the growth of the market in the region.

2- On the basis of drug type, antihistamine is anticipated to command for over one-third revenues share of the market by the end of 2017. Antihistamines drugs help in restricting the histamine release from histamine-1 receptors, moreover these drugs can effectively treat watery eyes or runny nose, inflammation (redness), sneezing and swelling (edema).

3- By OCT channel, pharmacies will continue to be the top OCT channel for sales of allergy, cold and cough drugs between 2017 and 2022. During the same time, the drug store segment is projected to retain its second spot.

4- Based on dosage, the tablet segment is projected to command for a significant share of the market in terms of revenue and is likely to reach a valuation of nearly US$ 12,425 Mn over 2022.

Competition Tracking

Fact.MR has profiled some of the key players in its report, which include Allergen, Bristol-Myers Squib Co., Prestige Brands Holdings, Inc., Pfizer Inc., GlaxoSmithKline Plc., Reckitt Benckiser Group Plc., AstraZaneca Plc., Johnson & Johnson Service, Inc., Procter & Gamble Co., Sanofi-Aventis, Novartis AG, Merck & Co., and Sun Pharmaceutical Industries Ltd. Many of these companies are concentrating on improving the product efficiency in order to increase their market presence.

Browse Full Report With TOC- https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-marketFACT.MR has been actively involved in offering comprehensive research data concerning various topics which are associated to industrial reference and investor utility. This particular research report titled “OTC Cough, Cold & Allergy Medicine Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022” has been added to the wide online database of FACT.MR which discusses the present as well as future market scenario. Readers can access knowledge related to market volume, regional expanse as well as competitive landscape prevailing in the global OTC Cough, Cold & Allergy Medicine market. In order to study development patterns, this smart assessment also focuses on market dynamics, which talks about drivers, restraints and opportunities estimated to influence the concerned market during the period until 2017 to 2022.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=71

Following insights from Fact.MR’s global OTC cough, cold and allergy market will be important for market’s future growth

1- The OTC cough, cold and allergy medicines market in Asia Pacific excluding Japan (APEJ) is anticipated to remain highly attractive throughout the assessment period. In 2017 and beyond, the region is projected to command for a noteworthy revenue share of the global market. This is primarily owing to dropping air quality and increase pollution that is resulting in higher occurrence of respiratory ailments. In addition, rapid adoption of OTC medicines owing to their convenience of purchase and cost-efficiency is facilitating the growth of the market in the region.

2- On the basis of drug type, antihistamine is anticipated to command for over one-third revenues share of the market by the end of 2017. Antihistamines drugs help in restricting the histamine release from histamine-1 receptors, moreover these drugs can effectively treat watery eyes or runny nose, inflammation (redness), sneezing and swelling (edema).

3- By OCT channel, pharmacies will continue to be the top OCT channel for sales of allergy, cold and cough drugs between 2017 and 2022. During the same time, the drug store segment is projected to retain its second spot.

4- Based on dosage, the tablet segment is projected to command for a significant share of the market in terms of revenue and is likely to reach a valuation of nearly US$ 12,425 Mn over 2022.

Competition Tracking

Fact.MR has profiled some of the key players in its report, which include Allergen, Bristol-Myers Squib Co., Prestige Brands Holdings, Inc., Pfizer Inc., GlaxoSmithKline Plc., Reckitt Benckiser Group Plc., AstraZaneca Plc., Johnson & Johnson Service, Inc., Procter & Gamble Co., Sanofi-Aventis, Novartis AG, Merck & Co., and Sun Pharmaceutical Industries Ltd. Many of these companies are concentrating on improving the product efficiency in order to increase their market presence.

Browse Full Report With TOC- https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-market